Sign In
Buy TGVSF
Tryg AS Earnings Calls
| Release date | Jul 10, 2026 |
| EPS estimate | $0.186 |
| EPS actual | $0.216 |
| EPS Surprise | 16.22% |
| Revenue estimate | 1.623B |
| Revenue actual | 1.615B |
| Revenue Surprise | -0.489% |
| Release date | Apr 15, 2026 |
| EPS estimate | $0.213 |
| EPS actual | $0.241 |
| EPS Surprise | 12.75% |
| Revenue estimate | 1.613B |
| Revenue actual | 1.6B |
| Revenue Surprise | -0.84% |
| Release date | Jan 22, 2026 |
| EPS estimate | $0.300 |
| EPS actual | $0.328 |
| EPS Surprise | 9.45% |
| Revenue estimate | 1.617B |
| Revenue actual | 1.615B |
| Revenue Surprise | -0.150% |
| Release date | Oct 10, 2025 |
| EPS estimate | $0.368 |
| EPS actual | $0.381 |
| EPS Surprise | 3.56% |
| Revenue estimate | 1.616B |
| Revenue actual | 1.595B |
| Revenue Surprise | -1.29% |
Last 4 Quarters for Tryg AS
Below you can see how TGVSF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 10, 2025 |
| Price on release | $22.93 |
| EPS estimate | $0.368 |
| EPS actual | $0.381 |
| EPS surprise | 3.56% |
| Date | Price |
|---|---|
| Oct 06, 2025 | $22.93 |
| Oct 07, 2025 | $22.93 |
| Oct 08, 2025 | $22.93 |
| Oct 09, 2025 | $22.93 |
| Oct 10, 2025 | $22.93 |
| Oct 13, 2025 | $22.93 |
| Oct 14, 2025 | $22.93 |
| Oct 15, 2025 | $22.93 |
| Oct 16, 2025 | $22.93 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Jan 22, 2026 |
| Price on release | $25.12 |
| EPS estimate | $0.300 |
| EPS actual | $0.328 |
| EPS surprise | 9.45% |
| Date | Price |
|---|---|
| Jan 15, 2026 | $25.12 |
| Jan 16, 2026 | $25.12 |
| Jan 20, 2026 | $25.12 |
| Jan 21, 2026 | $25.12 |
| Jan 22, 2026 | $25.12 |
| Jan 23, 2026 | $25.12 |
| Jan 26, 2026 | $25.12 |
| Jan 27, 2026 | $25.12 |
| Jan 28, 2026 | $25.12 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Apr 15, 2026 |
| Price on release | $23.75 |
| EPS estimate | $0.213 |
| EPS actual | $0.241 |
| EPS surprise | 12.75% |
| Date | Price |
|---|---|
| Apr 09, 2026 | $23.75 |
| Apr 10, 2026 | $23.75 |
| Apr 13, 2026 | $23.75 |
| Apr 14, 2026 | $23.75 |
| Apr 15, 2026 | $23.75 |
| Apr 16, 2026 | $23.75 |
| Apr 17, 2026 | $23.75 |
| Apr 20, 2026 | $23.75 |
| Apr 21, 2026 | $23.75 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Jul 10, 2026 |
| Price on release | $23.75 |
| EPS estimate | $0.186 |
| EPS actual | $0.216 |
| EPS surprise | 16.22% |
| Date | Price |
|---|---|
| Jul 06, 2026 | $23.75 |
| Jul 07, 2026 | $23.75 |
| Jul 08, 2026 | $23.75 |
| Jul 09, 2026 | $23.75 |
| Jul 10, 2026 | $23.75 |
| Jul 13, 2026 | $23.75 |
| Jul 14, 2026 | $23.75 |
| Jul 15, 2026 | $23.75 |
| Jul 16, 2026 | $23.75 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Tryg AS Earnings Call Transcript Summary of Q2 2026
Tryg reported a strong Q2 with revenue growth of 3.3% (5% in Private) and an adjusted insurance service result of DKK 2.39bn (DKK 1.19bn reported including a DKK 1.2bn one-off workers' compensation charge). The adjusted combined ratio was an excellent 77.4% driven by very strong Norway and Sweden performance and a 50 bps improvement in the underlying claims ratio (60 bps in Private). Investment result was DKK 262m; property exposure was reduced by DKK 450m pro forma (to ~DKK 1.9bn) and proceeds reinvested into low-risk covered bonds. Operating EPS was DKK 3.2 and DPS was DKK 2.15; solvency ratio remained robust at 196%. Management updated 2026 revenue guidance to around +3% (H2 expected weaker than H1) and reiterated confidence that growth will accelerate in 2027 and should exceed current market expectations, while cautioning that accelerated growth may slightly dampen short-term underlying improvement. The company continues to prioritize disciplined, profitable growth, execution of commercial partnerships (e.g., SAS EuroBonus, Lederne), cost efficiency, and a low-risk investment strategy.
